Skip to main content
editorial
. 2006 Jun 14;12(22):3461–3465. doi: 10.3748/wjg.v12.i22.3461

Figure 5.

Figure 5

Hepatic vascular transit times (HVTT) following a bolus injection of a microbubble contrast agent, measured in a volunteer without significant liver disease (upper graph) and a patient with cirrhosis (lower graph). There is a much shorter HVTT in the patient with cirrhosis. Adapted from Lim et al[23].

HHS Vulnerability Disclosure